I-131 MIBG therapy has been used as the first line therapy in pheochromocytoma
Conclusions: I-131 MIBG therapy can be used as a neoadjuvant therapy to reduce tumor mass and size, and thus is also a first line treatment. Both our patients had an improvement in their functional aspect of life and also had no hypertensive crises or tumor lysis syndrome even though both had a large tumor burden. Thus we conclude that I-131 MIBG is a safe therapy and should be considered preoperatively to reduce tumor size if it is needed. MIBG therapy can be used as a neoadjuvant therapy to reduce tumor mass and size, and thus is also a first line treatment.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Dhingra, J., Halkar, R. Tags: Endocrine/Neuroendocrine (Therapy/Non-Therapy) Poster Session Source Type: research
More News: Brain | Cancer & Oncology | Chemotherapy | External Beam Therapy | HNPCC | Hypertension | Hysterectomy | Liver | Lynch Syndrome | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Netherlands Health | Neuroblastoma | Neurology | Neurosurgery | Nuclear Medicine | Pain | Paraganglioma | PET Scan | Pheochromocytoma | SPECT | Ultrasound | Urology & Nephrology